Two patients in the no study drug arm and one in the favipiravir arm had raised creatinine phosphokinase (CPK) levels (> 10 times ULN) attributed to COVID-19-related skeletal muscle damage. The gene discussed is PIK3C2A; the disease is COVID-19.